IP Library › Granted Patent US 12,514,696
Granted Patent B2
US 12,514,696 · App. 17/921,888 · Granted Jan 6, 2026

Conformal coating of cells for immunoisolation

Inventors: Alice A. Tomei (Miami, FL); Aaron Stock (Miami, FL); Michael Lupp (Miami, FL)
Assignee: University of Miami
A61F2/022A61K35/39A61L27/34A61L27/38A61L27/3804A61L2300/64A61L2420/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,514,696
App. No.
17/921,888
Granted
Jan 6, 2026
Kind
B2
Abstract

Hydrodynamic methods for conformally coating non-uniform size cells and cell clusters with biomaterials for implantation, thus preventing immune rejection or inflammation or autoimmune destruction while preserving cell functionality, are disclosed. Further disclosed are reagents, apparatus, and methods for conformally coating cells and cell clusters with hydrogels that are biocompatible, mechanically and chemically stable and porous, with an appropriate pore cut-off size.

Claims (39)

1 . A method of conformally coating a biomaterial with a coating material, comprising the steps of:

(a) preparing an aqueous phase comprising a minimally crosslinked coating material and a biomaterial, and having a pH of about 6 to about 7.4; wherein the aqueous phase does not comprise a viscosity-enhancing agent;

(b) coaxially injecting the aqueous phase and an oil phase through a coating device, thereby forming an aqueous phase jet surrounded by the oil phase; wherein the aqueous phase jet breaks up into particles of biomaterial surrounded by the coating material as it moves downstream through the coating device;

(c) coaxially injecting a gelling emulsion into the coating device external to the oil phase and downstream of breakup of the aqueous phase jet into particles; wherein the gelling emulsion promotes or catalyzes polymerization of the coating material surrounding the biomaterial, thereby resulting in conformally coated biomaterial.

2 . The method of claim 1 , further comprising, after step (c):

(1) collecting the outflow of the coating device;

(2) purifying the conformally coated biomaterial and biomaterial-free coating material from the oil phase; and/or

(3) separating the conformally coated biomaterial from the biomaterial-free coating material.

3 . The method of claim 1 , wherein the biomaterial comprises cells, cell clusters, biomaterial-coated cells or cell-clusters, subcellular organelles, biologic molecules, non-biologic drugs, or a combination thereof.

4 . The method of claim 1 , wherein the coating material comprises an agent selected from the group consisting of polyethylene glycol (PEG), polyethylene oxide (PEO), poly(N-vinyl pyrrolidinone) (PVP), polyethyl oxazoline, polyvinyl alcohol (PVA), polythyloxazoline (PEOX), poly(amino acids), derivatives thereof and combinations thereof.

5 . The method of claim 4 , wherein the coating material comprises an agent selected from the group consisting of polyethylene glycol (PEG), PEG-maleimide, PEG-acrylate, and PEG-vinyl sulfone.

6 . The method of claim 5 , wherein the coating material comprises 5-10% PEG.

7 . The method of claim 1 , wherein the aqueous phase comprises;

(a) serum-free media at pH 6-7.4; or

(b) Hanks' Balanced Salt Solution (HBSS) at pH 6-7.4.

8 . The method of claim 7 , wherein the aqueous phase comprises;

(1) about 200,000,000 islet cells/mL; or

(2) about 100,000 cell clusters/mL.

9 . The method of claim 1 , wherein the aqueous phase comprises a thiolated reagent, a reducing reagent, a surfactant, or a combination thereof.

10 . The method of claim 9 , wherein the surfactant is polyoxyethylenepolyoxypropylene block copolymer or poly(ethylene glycol-bl-propylene sulfide).

11 . The method of claim 9 , wherein the reducing reagent is dithiothreitol (DTT) or PEGdiThiol.

12 . The method of claim 1 , wherein the gelling emulsion comprises dithiothreitol (DTT) dissolved in Hanks' Balanced Salt Solution (HBSS) and emulsified in polypropylene glycol (PPG) with 10% sorbitan mono oleate (Span80).

13 . The method of claim 1 , wherein the oil phase comprises polypropylene glycol (PPG).

14 . The method of claim 2 , wherein purification of the conformally coated biomaterial and the biomaterial-free coating material from the oil phase comprises pouring the product from step (c) into mineral oil while stirring the resultant mixture.

15 . The method of claim 1 , wherein the minimally crosslinked coating material is 1-30% crosslinked.

16 . A biomaterial conformally coated by the method of claim 1 .

17 . A method of cell therapy, the method comprising implanting the conformally coated biomaterial of claim 16 into a patient.

18 . A conformal coating device comprising:

(1) an encapsulation chamber comprising:

(a) a housing portion comprising a first inlet coupled to a catheter at a first end of the housing portion, wherein the catheter is connected to a first pump;

(b) an attachment portion comprising a first end coupled to a second end of the housing portion; and

(c) a coating portion comprising a first end coupled to a second end of the attachment portion, a chamber, a second inlet coupled to a second pump, and a second end;

wherein the catheter connected to the first pump is configured to inject an aqueous phase comprising a minimally crosslinked coating material and a biomaterial into the chamber, wherein the aqueous phase has a pH of about 6 to about 7.4 and

does not comprise a viscosity-enhancing agent;

wherein the second pump is configured to coaxially inject an oil phase external to the aqueous phase into the chamber through the second inlet;

(2) a capillary coupled to the second end of the coating portion, wherein the aqueous phase forms an aqueous jet phase which breaks up into particles of biomaterial surrounded by the coating material as it moves downstream through the capillary; and

(3) a third pump coupled to the capillary downstream of breakup of the aqueous phase jet into particles and configured to coaxially inject a gelling emulsion into the capillary external to the oil phase, wherein the gelling emulsion promotes or catalyzes polymerization of the coating material surrounding the biomaterial, thereby resulting in conformally coated biomaterial.

19 . The device of claim 18 , wherein the first end of the coating portion substantially surrounds the second end of the attachment portion, thereby forming the chamber.

20 . The device of claim 18 , wherein the second end of the attachment portion is tapered, thereby forming a tapered portion of the chamber configured to flow to the capillary, and wherein the second inlet is positioned at the tapered portion of the chamber.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2022
From: TOMEI, ALICE A.; STOCK, AARON; LUPP, MICHAEL
To: UNIVERSITY OF MIAMI
Reel/Frame 061583/0788 →
Continuity (1)
Related Publication 20230165669A1 · Jun 1, 2023
References Cited (57)
US 6558665B1 · Cohen · 2003 [cited by applicant]
US 6716246B1 · Gonzalez · 2004 [cited by applicant]
US 6911227B2 · Hubbell · 2005 [cited by applicant]
US 10653816B2 · Hubbell · 2020 [cited by applicant]
US 10660987B2 · Hubbell · 2020 [cited by applicant]
US 11207444B2 · Hubbell · 2021 [cited by applicant]
US 11623021B2 · Hubbell et al. · 2023 [cited by applicant]
US 20040195710A1 · Hubbell · 2004 [cited by applicant]
US 20060024276A1 · Ricordi · 2006 [cited by applicant]
US 20090014360A1 · Toner · 2009 [cited by applicant]
US 20090175927A1 · Gammelstaeter · 2009 [cited by applicant]
US 20110165219A1 · Barkai · 2011 [cited by applicant]
US 20110285042A1 · Viovy · 2011 [cited by applicant]
US 20140147483A1 · Hubbell · 2014 [cited by applicant]
US 20150071997A1 · Garcia · 2015 [cited by applicant]
US 20170216489A1 · Hubbell · 2017 [cited by applicant]
US 20210030922A1 · Hubbell · 2021 [cited by applicant]
WO WO1993021266 · 1993 [cited by applicant]
WO WO1997016176 · 1997 [cited by applicant]
WO WO2005103106 · 2005 [cited by applicant]
WO WO2012149496 · 2012 [cited by applicant]
Anna et al., “Formation of Dispersions Using ‘Flow Focusing’ in Microchannels,” Applied Physics Letters, 82(3):364-366 (2003). [cited by applicant]
Barrero et al., “Micro- and Nanoparticles via Capillary Flows,” Annual Review of Fluid Mechanics, 39(1):89-106 (2007). [cited by applicant]
Beck et al., “Islet encapsulation: Strategies to Enhance Islet Cell Functions,” Tissue Engineering, 13(3):1-11 (2007). [cited by applicant]
Buchwald et al., “Glucose-stimulated insulin release: Parallel perifusion studies of free and hydrogel encapsulated human pancreatic islets,” Biotechnol. Bioeng, 115(1):232-245 (2018). [cited by applicant]
Buchwald et al., “Experimental evaluation and computational modeling of the effects of encapsulation on the time-profile of glucose-stimulated insulin release of pancreatic islets,” Biomed. Engineer. Online 14: 28 (2015… [cited by applicant]
Cellesi “New fully synthetic materials for cell encapsulation,” Doctoral Thesis, ETH Zurich [online], 2003 [Retrieved on Jul. 2, 2012], pp. 1-130. [cited by applicant]
Chabert et al., “Microfluidic high-throughput encapsulation and hydrodynamic self-sorting of single cells,” PNAS, 105:3191-3196 (2008). [cited by applicant]
Chang et al., “The in vivo delivery of heterologous proteins by microencapsulated recombinant cells,” Trends in Biotechnology, 17:78-83 (1999). [cited by applicant]
Cohen et al., “Using selective withdrawal to coat microparticles,” Science, 292:265-267 (2001). [cited by applicant]
De Groot et al., “Causes of limited survival of microencapsulated pancreatic islet grafts,” Journal of Surgical Research, 121:141-150 (2004). [cited by applicant]
Desai et al., “Advances in islet encapsulation technologies,” Nat Rev Drug Discov 16: 338-350 (2017). [cited by applicant]
De Vos et al., “Treatment of diabetes with encapsulated islets,” Advances in Experimental Medicine and Biology, 670:3853 (2010). [cited by applicant]
Eggleton et al., “Tip streaming from a drop in the presence of surfactants,” Physical Review Letters, 87:048302 (2001). [cited by applicant]
Foster et al., “Improved Health-Related Quality of Life in a Phase 3 Islet Transplantation Trial in Type 1 Diabetes Complicated by Severe Hypoglycemia,” Diabetes Care, 41:1001-1008 (2018). [cited by applicant]
Hering et al., “Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia,” Diabetes Care, 39:1230-1240 (2016). [cited by applicant]
Kim et al., “Synthesis and Characterization of Injectable Poly(N-isopropylacrylamide-co-acrylic acid) Hydrogels with Proteolytically Degradable Cross-Links,” Biomacromolecules, 4(5):1214-1223 (2003). [cited by applicant]
Korsgren, “Islet Encapsulation: Physiological Possibilities and Limitations,” Diabetes, 66:1748-1754 (2017). [cited by applicant]
LaBlanche et al., “Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised… [cited by applicant]
Loscertales et al., “Micro/nano encapsulation via electrified coaxial liquid jets,” Science, 295:1695-1698 (2002). [cited by applicant]
Manzoli et al., “Immunoisolation of murine islet allografts in vascularized sites through conformal coating with polyethylene glycol,” Am. J. Transplant, 18(3):590-603 (2018). [cited by applicant]
Minguez-Castellanos et al., “Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study,” Journal of Neurology, Neurosurgery, and Psychiatry , 78(8):825831 (2007). [cited by applicant]
Pepper et al., “Clinical islet transplantation: is the future finally now?,” Curr. Opin. Organ Transplant, 23:428-439 (2018). [cited by applicant]
Rabanel et al., “Progress technology in microencapsulation methods for cell therapy,” Biotechnology Progress, 25:946-963 (2009). [cited by applicant]
Rickels et al., “Pancreatic Islet Transplantation in Humans: Recent Progress and Future Directions,” Endocrin. Rev. 40:631-668 (2019). [cited by applicant]
Rinsch et al., “Delivery of erythropoietin by encapsulated myoblasts in a genetic model of severe anemia,” Kidney Intern, 62:1395-1401 (2002). [cited by applicant]
Robertson, “Update on transplanting beta cells for reversing type 1 diabetes,” Endocrinology and Metabolism Clinics of North America, 39:655-667 (2010). [cited by applicant]
Shapiro et al., “Clinical pancreatic islet transplantation,” Nat. Rev. Endocrinol., 13: 268-277 (2017). [cited by applicant]
Smink et al., “Polymer scaffolds for pancreatic islet transplantation—Progress and challenges,” Am J. Tranplant 18: 2113-2118 (2018). [cited by applicant]
Stock et al., “Conformal Coating of Stem Cell-Derived Islets for β Cell Replacement in Type I Diabetes,” Stem Cell Reports 14: 91-104 (2020). [cited by applicant]
Teramura et al., “Bioartificial pancreas-Microencapsulation and conformal coating of islet of Langerhans,” Advanced Drug Delivery Reviews, 62:827-840 (2010). [cited by applicant]
Tomei et al., “Device design and materials optimization of conformal coating for islets of Langerhans,” Proc. Nat. Acad. Sci. USA, 111:10514-10519 (2014). [cited by applicant]
Tomei et al., “Development of an Encapsulated Stem Cell-Based Therapy for Diabetes,” Expert. Opin. Biol. Ther. 15: 1321-1326 (2015). [cited by applicant]
Utada et al., “Absolute instability of a liquid jet in a coflowing stream,”Physical Review Letters, 100:014502 (2008). [cited by applicant]
Vaithilingam et al., “Encapsulated Islet Transportation: Where Do We Stand?,” Rev Diabetes Stud 14: 51-78 (2017). [cited by applicant]
Villa et al., “Effects of Composition of Alginate-Polyethylene Glycol Microcapsules and Transplant Site on Encapsulated Islet Graft Outcomes in Mice,” Transplantation, 101(5):1025-1035 (2017). [cited by applicant]
Wyman et al., “Immunoisolating pancreatic islets by encapsulation with selective withdrawal,” Small, 3:683-690 (2007). [cited by applicant]